Publications and Presentations

Learn more about our scientific and clinical research.

• SITC: NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo
• SITC: Epi-R™ Technology Produces a Polyclonal TIL Product (LYL845) With Diverse Tumor-Reactive Clones That Have Stem-Like Qualities and Anti-Tumor Function
• SITC: Epi-R™ Technology Produces a Polyclonal TIL Product (LYL845) With a Greater Expansion Success Rate Across Hot and Cold Tumors, Improved Product Phenotype, and Maintenance of TCR Diversity
• SITC: Engineering Potent CAR T-Cell Therapies by Controlling T-Cell Activation Signaling Parameters Using the Stim-R™ Technology, a Programmable Synthetic Cell-Signaling Platform
• SITC: Increased Potency and Functional Persistence in vitro of a Next-Generation NY-ESO-1—specific TCR Therapy Incorporating Gen-R™ Genetic Reprogramming Technology
• ESMO: Phase 1 Study of LYL797, a ROR1-Targeted CAR T-Cell Therapy With Genetic and Epigenetic Reprogramming for the Treatment of Advanced Solid Tumors
• ISSCR: T-Cell Rejuvenation: A Novel Approach for Partially Reprogramming T Cells to Improve Their Immunotherapeutic Properties
• ASGCT: Epigenetic reprogramming (Epi-R™) yields an NY-ESO-1 T-cell receptor product (LYL132; GSK4427296) with improved stemness, metabolic fitness, and functional activity in the presence of persistent antigen exposure
• ASGCT: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors
• AACR 2022: LYL797, a ROR1 CAR T-Cell Therapy With Genetic and Epigenetic Reprogramming for Solid Tumors